The immunoglobulin γ marker 17 allotype and KIR/HLA genes prevent the development of chronic hepatitis B in humans

Summary Hepatitis B virus (HBV) infection causes a self‐limiting disease in most individuals. However, < 10% of infected subjects develop a chronic disease. Genetic host variability of polymorphic genes at the interface of innate and acquired immunity, such as killer immunoglobulin‐like receptors...

Full description

Saved in:
Bibliographic Details
Published inImmunology Vol. 159; no. 2; pp. 178 - 182
Main Authors Di Bona, Danilo, Pandey, Janardan P., Aiello, Anna, Bilancia, Massimo, Candore, Giuseppina, Caruso, Calogero, Colomba, Claudia, Duro, Giovanni, Ligotti, Mattia Emanuela, Macchia, Luigi, Rizzo, Sergio, Accardi, Giulia
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.02.2020
John Wiley and Sons Inc
Subjects
Online AccessGet full text
ISSN0019-2805
1365-2567
1365-2567
DOI10.1111/imm.13133

Cover

More Information
Summary:Summary Hepatitis B virus (HBV) infection causes a self‐limiting disease in most individuals. However, < 10% of infected subjects develop a chronic disease. Genetic host variability of polymorphic genes at the interface of innate and acquired immunity, such as killer immunoglobulin‐like receptors (KIR), their human leucocyte antigen (HLA) and IgG allotypes (GM), could explain this different clinical picture. We previously showed a protective role of the KIR2DL3 gene for the development of chronic hepatitis B (CHB), and a detrimental role of the KIR ligand groups, HLA‐A‐Bw4 and HLA‐C2. We have expanded the previous analysis genotyping patients for GM23 and GM3/17 allotypes. The comparison of the patients with CHB with those who resolved HBV infection showed that the presence of GM17 allele virtually eliminated the risk of developing CHB (OR, 0·03; 95% CI, 0·004–0·16; P < 0·0001). In addition, the combination of GM17, KIR2DL3, HLA‐A‐Bw4 and HLA‐C2 was highly sensitive to predict the outcome of HBV infection. Logistic regression model to predict CHB development in the complete case database (n = 88).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
D.D.B. and J.P.P. contributed equally to this study.
ISSN:0019-2805
1365-2567
1365-2567
DOI:10.1111/imm.13133